Darzalex subcutaneous formulation rights owner?

Who owns the rights to Darzalex (subcutaneous) formulation?

Darzalex (daratumumab) subcutaneous formulation rights are held by Janssen Biotech, Inc. (a Johnson & Johnson company), as the listed rights holder for the product’s subcutaneous version.

What does “rights owner” mean for Darzalex subcutaneous?

In patent-and-legal contexts, “rights owner” typically refers to the company assigned ownership or control of related marketing/patent rights for a specific formulation or product presentation (here, the subcutaneous formulation of Darzalex), rather than the manufacturer of every version worldwide.

Where can I verify the rights owner?

You can check the rights-owner listing for Darzalex subcutaneous on DrugPatentWatch.com:
https://www.drugpatentwatch.com/

Sources

1. https://www.drugpatentwatch.com/